Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, Marcella Kaddoura, Alexandra Maria Poos, Anthony Cirrincione, Benjamin Diamond, Kylee H Maclachlan, Bachisio Ziccheddu, Elias K. Mai, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Gareth J. Morgan, Saad Z Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold

Blood (2023) 142 (Supplement 1): 638.

https://doi.org/10.1182/blood-2023-182267

Published: 2023

Journal Articles

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

Blood (2023) 142 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2023-189316

Published: 2023

Journal Articles

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Holly Lee, Michael Durante, Sungwoo Ahn, Noemie Leblay, Mansour Poorebrahim, Ranjan Maity, Rémi Tilmont, Elie Barakat, David Jung, Bachisio Ziccheddu, Alexis Brake, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2023-188080

Published: 2023

Journal Articles

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Benjamin Diamond, Niccolò Bolli, Paolo Corradini, David Coffey, Ola Landgren, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca

Blood (2023) 142 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2023-182301

Published: 2023

Journal Articles

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Andrew Kowalski, Jillian Lorayne Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2023) 142 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2023-187086

Published: 2023

Journal Articles

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, Sungwoo Ahn, Ranjan Maity, Noémie Leblay, Michael Durante, Bachisio Ziccheddu, Alexis Brake, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2023-190517

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Journal Articles

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Blood (2023) 142 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2023-190882

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Monika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, Even Rustad, Eileen Boyle, Kylee H Maclachlan, Patrick Blaney, Saad Usmani, Gareth J. Morgan, Ola Landgren, Francesco Maura

Blood (2022) 140 (Supplement 1): 1542–1543.

https://doi.org/10.1182/blood-2022-160311

Published: 2022

Journal Articles

Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

Blood (2022) 140 (Supplement 1): 249–251.

https://doi.org/10.1182/blood-2022-165500

Published: 2022

Journal Articles

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Benjamin Diamond, Alexandra M Poos, Bachisio Ziccheddu, Kylee H Maclachlan, Yanming Zhang, Saad Usmani, Eileen M Boyle, Faith E Davies, Gareth J. Morgan, Ola Landgren, Marc S Raab, Francesco Maura, Niels Weinhold

Blood (2022) 140 (Supplement 1): 7125–7126.

https://doi.org/10.1182/blood-2022-166531

Published: 2022

Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Blood (2022) 140 (Supplement 1): 2088–2090.

https://doi.org/10.1182/blood-2022-158992

Published: 2022

Journal Articles

Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients

Neha Korde, Benjamin Diamond, Miranda Burge, Hani Hassoun, Heather Landau, Malin Hultcrantz, Sham Mailankody, Kylee H Maclachlan, Urvi A Shah, Andriy Derkach, Saad Usmani, Ola Landgren, Alexander Lesokhin

Blood (2022) 140 (Supplement 1): 2397–2398.

https://doi.org/10.1182/blood-2022-169937

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

NARROW

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only